Cambridge Healthtech Institute’s 6th Annual

Cell Therapy Manufacturing

Commercializing Cell-Based Therapies

August 14-15, 2019


Cell therapy is one of the most exciting areas of biotech today. But how will we manufacture these products at scale? And what platforms, technologies and cell processes can we expect to see in the future? Do the answers lie in traditional biomanufacturing methods or custom-made processes?

CHI’s Cell Therapy Manufacturing conference takes an in-depth look at the practical challenges of manufacturing autologous and allogenic cell therapies at scale, with dedicated sessions on cell processing, scalability, bioreactors, next-generation production technologies, automation, closed systems, supply chain and facility design. The meeting will feature extensive sessions on autologous and allogeneic production platforms, CAR Ts, NK cells, TCRs and manufacturing CRISPR-based CAR Ts at scale.

Preliminary Agenda

REDUCING COST OF GOODS

CAR T Cell Therapy Manufacturing at Commercial Scale

Jean-Pierre Latere, COO, Celyad

Manufacturing Cell Therapies

Knut Niss, PhD, CTO, Mustang Bio

Process Development and Scaling up of CAR T Therapies

Fabio Fachin, PhD, Vice President, Manufacturing, Torque Therapeutics

Presentation to be Announced, by Unum

NEXT GENERATION CELL THERAPY MANUFACTURING – NEW TECHNOLOGIES AND MODALITIES

Developing Allogeneic NK Cell Therapies with iPSC Technology

Wen Bo Wang, PhD, Senior Vice President, Technical Operations, Fate Therapeutics

Next-Generation Cell Therapy Manufacturing

Lan Cao, PhD, Senior Director, Head Product Development and Manufacturing, Cell Therapy, Takeda

Next-Generation Cell Therapy Manufacturing

Juan Vera, PhD, Chief Development Officer, Marker Therapeutics

Talk Title to be Announced

Ravi Bhatia, PhD, Scientific Director, Janssen

Optimizing Antigen-Specific T Cell Manufacturing

Patrick J. Hanley, PhD, Laboratory Facility Director, Cellular Therapy and Stem Cell Processing, Program for Cell Enhancement and Technologies for Immunotherapy, Division of Blood and Marrow Transplantation, Children’s National Health System


* The program is subject to change without notice, due to unforeseen reason.